Multiple Myeloma News & Features
Improved progression-free survival in relapsed multiple myeloma has been seen with the addition of carfilzomib to lenalidomide and dexamethasone therapy.
Recent therapeutic progress has improved outcomes for patients with myeloma; however, the complex biology of this disease continues to challenge treatment.
A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.
Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.
A high incidence of one or more subclinical quantitative sensory test deficits are seen in treatment-naive patients.
Multiple Myeloma Clinical Trials
- Key discovery in understanding successes and failures of immunotherapy
- Added sugars may increase blood pressure more than high salt consumption
- Researchers identify biological indicator of response to new ovarian cancer drug
- Managing obesity should be part of cancer care
- Galeterone active in one form of castration-resistant prostate cancer
- Importance of sequence in administering premeds with paclitaxel
- Tamoxifen found to lower breast cancer rates among high-risk women in trial
- SABCS: Male breast cancer prognosis falls behind that for women
- Pembrolizumab safe, and even effective in some patients, for triple-negative breast cancer
- Capecitabine does not improve survival in elderly patients with early stage breast cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|